[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-436066-105":59,"doc-detail-436066-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-therapeutic-strategies-and-survival-outcomes-in-advanced-her2-mutant-non-small-cell-lung-cancer-abstract-methods-results-conclusion","Real-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer - Abstract - Methods - Results - Conclusion","","Real-world therapeutic strategies and survival outcomes are examined for advanced HER2-mutant non-small cell lung cancer in Taiwan, where treatment options are expanding yet local evidence remains limited. Data from patients receiving systemic therapy for advanced or recurrent disease between 2011 and 2021 were followed through 2022. Clinical features, treatment responses, and survival factors were analyzed to clarify which first-line regimens better relate to progression-free and overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-therapeutic-strategies-and-survival-outcomes-in-advanced-her2-mutant-non-small-cell-lung-cancer-abstract-methods-results-conclusion/436066/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-therapeutic-strategies-and-survival-outcomes-in-advanced-her2-mutant-non-small-cell-lung-cancer-abstract-methods-results-conclusion/436066.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding HER2-mutant NSCLC in Taiwan?","Question",{"text":112,"@type":113},"To investigate clinical characteristics and outcomes of HER2-mutant NSCLC in a real-world setting in Taiwan.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and how long were they followed?",{"text":117,"@type":113},"Patients with advanced or recurrent HER2-mutant NSCLC who received systemic therapy from 2011 to 2021 were included, and follow-up continued until 2022 at two medical centers in Taiwan.",{"name":119,"@type":110,"acceptedAnswer":120},"What first-line treatment combinations showed better survival outcomes?",{"text":121,"@type":113},"First-line platinum-based chemotherapy combined with an immune checkpoint inhibitor (PC + ICI) was associated with longer progression-free survival than PC alone, and response rates were generally higher with PC + ICI.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},436066,1790874254,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","J Chin MedAssoc  \nOriginal article  \nReal-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer  \nRuei-Lin Suna,b, Pei-Ya Liaoc, Ying-Ting Liaoa,b, Yi-Chen Yehb,d, Chi-Lu Chianga,b, Yuh-Min Chena,b, Kuo-Hsuan Hsue, Jeng-Sen Tsengb,c,f,g, Hsu-Ching Huanga,b, Chia-I Shena,b, Yen-Han Tsenga,b, Yen-Hsiang Huangb,c,*, Yung-Hung Luoa,b,*, Tsung-Ying Yangc,f  \naDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cDivision of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC; dDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eDivision of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC; fDepartment of Life Sciences, National Chung Hsing University, Taichung, Taiwan, ROC; gDepartment of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, ROC  \nAbstract  \nBackground: Limited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment options for this distinct subtype. This study aimed to investigate the clinical characteristics and outcomes of HER2-mutant NSCLC in a real-world setting. Methods: Relevant data were collected from patients with advanced or recurrent HER2-mutant NSCLC who received systemic therapy between 2011 and 2021 and were followed up until 2022 at two medical centers in Taiwan. Clinical features, treatment responses, and survival-related factors were analyzed.  \nResults: This study included 45 patients (median age: 59.7 [range: 41.3-78.7] years) . A775_G776insYVMA was the most common HER2 mutation subtype (57 .8%), followed by G778_P780dup (11 . 1%) . Approximately 53 .3% of the patients received first-line platinum-based chemotherapy (PC) alone, whereas 13.3% received PC combined with an immune checkpoint inhibitor (ICI) . The median overall survival (OS) and progression-free survival (PFS) after first-line therapy were 25.8 and 4.4 months, respectively. The objective response rate was generally higher in patients receiving first-line PC + ICI than those receiving PC alone (33 .3% vs 12.5%; p = 0 .269) . Furthermore, patients receiving PC + ICI had longer PFS than those receiving PC alone (9 .5 vs 4.4 months; p = 0 . 131) and those receiving tyrosine kinase inhibitor/ICI monotherapy (9 .5 vs 0.5 months; p = 0 .015) . Compared with patients having other NSCLC subtypes, those carrying HER2 exon 20 insertion mutations had shorter median PFS (17 .3 vs 2.9 months; p = 0 .043) and OS (not reached vs 19 months; p = 0.031) .  \nConclusion: This study highlights the clinical features and outcomes of advanced HER2-mutant NSCLC in Taiwan. PC + ICI maybe more effective than other regimens as first-line therapy. The prognostic impact of HER2 exon 20 insertion mutations warrants further investigation.  \nKeywords: Immune checkpoint inhibitor; Non-small cell lung cancer; Prognostic; Progression-free survival; Tyrosine kinase inhibitor  \n[www.ejcma.org](www.ejcma.org) 307  \n\u003Cz10.1097/JCMA.0000000000001212>  \nSun et al. J Chin MedAssoc  \n1. INTRODUCTION  \nWith the identification of tumor-specific mutations that deregulate molecular signaling, progress has been made in the care of patients with advanced non-small cell lung cancer (NSCLC) . One such mutation occurs in the human epidermal growth factor receptor (EGFR) 2 gene (HER2; also called ErbB2) . The prevalence of HER2 mutation in patients with nonsquamous NSCLC is approximately 2% to 4%; it is slightly higher in Asian populations (1.4%-6.7%) than in European and American populations (1%-3%) .1–4  \nHER2 targeting has significantly tran","cbCaikqyc1ZzPBAN","https://ap.wps.com/l/cbCaikqyc1ZzPBAN","pdf",1006759,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods","[{\"question\":\"What was the study objective regarding HER2-mutant NSCLC in Taiwan?\",\"answer\":\"To investigate clinical characteristics and outcomes of HER2-mutant NSCLC in a real-world setting in Taiwan.\"},{\"question\":\"How were patients selected and how long were they followed?\",\"answer\":\"Patients with advanced or recurrent HER2-mutant NSCLC who received systemic therapy from 2011 to 2021 were included, and follow-up continued until 2022 at two medical centers in Taiwan.\"},{\"question\":\"What first-line treatment combinations showed better survival outcomes?\",\"answer\":\"First-line platinum-based chemotherapy combined with an immune checkpoint inhibitor (PC + ICI) was associated with longer progression-free survival than PC alone, and response rates were generally higher with PC + ICI.\"}]","Real-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer - Abstract - Methods - Results - Conclusion | PDF",1790676630,23]